SAB Biotherapeutics is trading at $2.87, down 5.59% on October 23, 2026, with biotech weakness a plausible contributor.
- No clear company-specific catalyst was identified. Its latest listed releases are dated October 14 and 13.
- An October 23 article covered executives discussing trial progress and the antibody platform, rather than announcing a major new event.
- XBI was down 2.08%; healthcare and biotechnology ETFs were also reported lower premarket, while broader indexes were mixed.